#1 Clinical Trials Search in Europe

Mometasone Furoate

Mometasone Furoate is a corticosteroid medication that has been studied extensively in clinical trials for its potential in treating various allergic conditions and asthma. This article explores the use of Mometasone Furoate in different formulations and dosages, examining its effectiveness, safety, and impact on patients’ quality of life across multiple studies.

Table of Contents

What is Mometasone Furoate?

Mometasone Furoate is a medication that belongs to a class of drugs called corticosteroids. Corticosteroids are synthetic versions of hormones naturally produced by the body’s adrenal glands. They are known for their powerful anti-inflammatory effects, which make them useful in treating various conditions involving inflammation[1]. Mometasone Furoate is also known by brand names such as Nasonex and Asmanex Twisthaler, and it may be referred to by its research code SCH 32088[2][3].

Conditions Treated by Mometasone Furoate

Mometasone Furoate is used to treat several conditions, including:

  • Allergic Rhinitis: This includes both seasonal (hay fever) and perennial (year-round) allergic rhinitis. Symptoms may include sneezing, runny nose, nasal congestion, and itching[1][2].
  • Asthma: Mometasone Furoate is used to treat mild to moderate persistent asthma in patients aged 12 years and older[3].
  • Atopic Dermatitis: Also known as eczema, this is a chronic skin condition characterized by itchy, inflamed skin[4].
  • Plaque Psoriasis: A condition causing red, scaly patches on the skin[5].

Forms and Administration

Mometasone Furoate is available in several forms, depending on the condition being treated:

  • Nasal Spray: Used for allergic rhinitis, typically administered as one or two sprays in each nostril once or twice daily[1][2].
  • Inhaler (Asmanex Twisthaler): Used for asthma, usually taken as one inhalation (200 or 400 mcg) once daily in the evening[3].
  • Cream or Ointment: Applied to the skin for conditions like atopic dermatitis or plaque psoriasis[4][5].

The exact dosage and frequency of use will depend on the specific condition being treated, its severity, and individual patient factors. Always follow your healthcare provider’s instructions or the directions on the product label.

Efficacy of Mometasone Furoate

Clinical trials have demonstrated the effectiveness of Mometasone Furoate in treating various conditions:

  • Allergic Rhinitis: Studies have shown that Mometasone Furoate nasal spray can significantly reduce nasal symptoms such as sneezing, runny nose, and congestion. It has been found to be effective for both seasonal and perennial allergic rhinitis[1][2].
  • Asthma: Research indicates that Mometasone Furoate inhalation powder can improve lung function and reduce asthma symptoms in patients with mild to moderate persistent asthma. It has been shown to increase Forced Expiratory Volume in 1 Second (FEV1), which is a measure of how much air a person can exhale in one second[3].
  • Skin Conditions: In studies on atopic dermatitis and plaque psoriasis, Mometasone Furoate cream or ointment has been shown to reduce inflammation, itching, and improve overall skin condition[4][5].

Potential Side Effects

While Mometasone Furoate is generally well-tolerated, like all medications, it can cause side effects in some people. Common side effects may include:

  • For nasal sprays: nasal irritation, nosebleeds, headache
  • For inhalers: throat irritation, cough, hoarseness
  • For creams/ointments: skin irritation, burning sensation, itching

More serious side effects are rare but can include increased risk of infections, changes in vision, or slowed growth in children. Always report any unusual or severe side effects to your healthcare provider[3].

Comparisons with Other Treatments

Several studies have compared Mometasone Furoate to other treatments:

  • For allergic rhinitis, Mometasone Furoate nasal spray has been compared to other nasal corticosteroids and found to be equally effective or superior in some cases[6].
  • In treating plaque psoriasis, a combination of Mometasone Furoate with salicylic acid has been studied and may offer improved efficacy compared to Mometasone Furoate alone[5].
  • For asthma, Mometasone Furoate inhalation powder has been compared to placebo and shown to provide significant improvements in lung function and symptom control[7].

Patient Considerations

When using Mometasone Furoate, patients should keep in mind:

  • Consistency: Regular use as prescribed is important for achieving the best results, especially for chronic conditions like asthma or allergic rhinitis[3].
  • Proper Technique: For nasal sprays and inhalers, correct administration technique is crucial for the medication to be effective. Your healthcare provider can demonstrate the proper technique[2].
  • Monitoring: Regular follow-ups with your healthcare provider are important to assess the medication’s effectiveness and adjust treatment if necessary[8].
  • Combination Therapy: In some cases, Mometasone Furoate may be used in combination with other medications for enhanced effect. For example, an antihistamine might be added to Mometasone Furoate nasal spray for better control of allergy symptoms[8].

Remember, while this information provides a general overview, always consult with your healthcare provider for personalized advice and information about using Mometasone Furoate for your specific condition.

Aspect Details
Conditions Studied Perennial allergic rhinitis, atopic dermatitis, asthma, plaque psoriasis
Formulations Nasal spray, cream, ointment, inhalation powder
Dosages Varied by study: 100-400 mcg daily for nasal spray, 400 mcg daily for asthma inhalation
Study Durations 2-24 weeks, with some long-term studies extending further
Primary Outcomes Symptom score changes, lung function improvements (FEV1), skin condition improvements
Secondary Outcomes Quality of life assessments, individual symptom improvements, treatment adherence
Study Designs Randomized, placebo-controlled, double-blind, parallel-group studies
Patient Demographics Adults and adolescents (12+ years in some studies), both sexes
Comparators Placebo, different formulations of Mometasone Furoate, combination therapies
Safety Assessments Adverse event monitoring, laboratory tests

FAQ

  • What conditions is Mometasone Furoate used to treat in these clinical trials? Mometasone Furoate is used to treat various conditions in these clinical trials, including perennial allergic rhinitis, atopic dermatitis, mild to moderate persistent asthma, and plaque psoriasis.
  • How is Mometasone Furoate typically administered in these studies? Mometasone Furoate is administered in various forms depending on the condition being treated. For allergic rhinitis, it's often used as a nasal spray. For skin conditions like atopic dermatitis and psoriasis, it's applied as a cream or ointment. For asthma, it's used as an inhalation powder.
  • What are some common outcomes measured in these clinical trials? Common outcomes measured include changes in symptom scores (such as nasal symptoms for allergic rhinitis), lung function tests like FEV1 for asthma, skin condition improvements for dermatological uses, and overall quality of life assessments.
  • Are there any side effects associated with Mometasone Furoate use in these trials? While specific side effects aren't detailed in the provided summaries, clinical trials typically monitor for adverse events. In general, corticosteroids like Mometasone Furoate may have side effects, but these trials aim to establish the safety profile of the medication.
  • How long do these clinical trials typically last? The duration of these clinical trials varies, but many last between 2 to 12 weeks. Some studies, particularly those examining long-term effects, may extend up to 24 weeks or longer.

Ongoing Clinical Trials on Mometasone Furoate

  • Study on Clobetasol, Mometasone, and Tacrolimus for Treating Vulvar Lichen Sclerosus in Children

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Study on Lebrikizumab for Adults with Chronic Rhinosinusitis and Nasal Polyps Using Intranasal Corticosteroids

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Denmark Finland Germany Hungary +5

  • Study on the Effectiveness and Safety of Indacaterol Acetate/Mometasone Furoate vs. Budesonide for Children Aged 6-11 with Asthma

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Bulgaria Czechia Greece Hungary Italy +3

  • Efficacy and safety of indacaterol acetate (combined with glycopyrronium bromide and mometasone furoate) versus salmeterol/fluticasone in adolescents with asthma

    Not yet recruiting

    3 1 1
    Investigated drugs:
    France Germany Hungary Poland Romania Slovakia +1

  • Evaluation of Alutard SQ dog allergen immunotherapy in patients with allergic rhinitis due to dog allergy – A one-year study in Swedish practice

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study of Mometasone Nasal Spray Treatment for Patients with Rhinitis Medicamentosa (Nasal Decongestant Dependency)

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Belgium

  • Study on the Effectiveness and Safety of Cyclosporine and Methotrexate for Children and Adolescents with Moderate to Severe Atopic Dermatitis

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Poland

  • Study of Lebrikizumab and Mometasone Furoate for Adults with Perennial Allergic Rhinitis

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany Poland

  • Study on the Effectiveness and Safety of 0.1% Mometasone Furoate Emulsion and Ecural Cream for Adults with Plaque Psoriasis

    Not recruiting

    3 1 1
    Investigated drugs:
    Poland

  • Study on the Effects of SAR443765 and Mometasone Furoate in Adults with Chronic Rhinosinusitis with Nasal Polyps

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Poland

Glossary

  • Perennial Allergic Rhinitis: A chronic condition causing year-round allergy symptoms such as sneezing, runny nose, and nasal congestion, typically triggered by indoor allergens like dust mites or pet dander.
  • Atopic Dermatitis: A chronic skin condition characterized by itchy, inflamed skin, commonly known as eczema.
  • FEV1 (Forced Expiratory Volume in 1 Second): A measure of lung function that represents the amount of air a person can forcefully exhale in one second, often used to assess the severity of asthma.
  • Corticosteroid: A class of steroid hormones used to reduce inflammation in various parts of the body, including the nasal passages, lungs, and skin.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare against the effects of the active drug being studied.
  • Randomized Clinical Trial: A study design where participants are randomly assigned to different treatment groups to compare the effects of different interventions.
  • Peak Expiratory Flow Rate (PEFR): A measure of how quickly a person can exhale air from their lungs, often used to monitor asthma control.
  • Quality of Life (QOL): A measure of an individual's overall well-being and ability to function in daily life, often assessed in clinical trials to determine the impact of a treatment.
  • Transepidermal Water Loss: The amount of water that passively evaporates through the skin, used as a measure of skin barrier function in dermatology studies.
  • Plaque Psoriasis: A common form of psoriasis characterized by raised, red patches covered with a silvery white buildup of dead skin cells, typically on the scalp, knees, elbows and lower back.

References

  1. https://clinicaltrials.gov/study/NCT04670653
  2. https://clinicaltrials.gov/study/NCT00779545
  3. https://clinicaltrials.gov/study/NCT00687531
  4. https://clinicaltrials.gov/study/NCT04271007
  5. https://clinicaltrials.gov/study/NCT01228656
  6. https://clinicaltrials.gov/study/NCT01702103
  7. https://clinicaltrials.gov/study/NCT00442351
  8. https://clinicaltrials.gov/study/NCT00834119